Matheus Rodrigues Lopes

Matheus Rodrigues Lopes

Auto-generated profile, based on publicly available information

Matheus Rodrigues Lopes

Universidade Federal do Vale do São Francisco, Brasil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2013 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
PFPatricia Favaro
Patricia Favaro
FTFabiola Traina
Fabiola Traina
JMJoão Agostinho Machado-Neto
João Agostinho Machado-Neto
MLMariana Lazarini
Mariana Lazarini
MLMatheus Rodrigues Lopes
Matheus Rodrigues Lopes
SSSara Teresinha Olalla Saad
Sara Teresinha Olalla Saad
The human FMNL1 is expressed predominantly in hematopoietic cells and has been described previously as overexpressed in hematopoietic malignancies. However, it is not known whether FMNL1 contributes to leukemogenesis. Here, we investigate the FMNL1 function using two different human leukemia models: Namalwa and K562 cell lines. FMNL1 depletion reduced cell proliferation and colony formation in both leukemic cell types, as well as a decrease in the tumor growth of FMNL1-depleted Namalwa cell xenografts. In addition, there was a decrease in migration and in TEM in FMNL1-depleted Namalwa cells. FMNL1 endogenously associates with Rac1, and FMNL1 silencing resulted in an increased Rac1 activity. The reduced migration observed in FMNL1-depleted cells was restored by inhibiting Rac activity. Our results indicate that FMNL1 stimulates leukemia cell proliferation as well as migration. This suggests that FMNL1 contributes to leukemogenesis and could act in part through Rac1 regulation.

13 January 2017 in Scientific Reports
Verified
Journal Article
Open access
MLMatheus Rodrigues Lopes
Matheus Rodrigues Lopes
JPJoão Kleber Novais Pereira
João Kleber Novais Pereira
PCPaula de Melo Campos
Paula de Melo Campos
JMJoão Agostinho Machado-Neto
João Agostinho Machado-Neto
FTFabiola Traina
Fabiola Traina
PFPatricia Favaro
Patricia Favaro
The interaction between the bone marrow microenvironment and malignant hematopoietic cells can result in the protection of leukemia cells from chemotherapy in both myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We, herein, characterized the changes in cytokine expression and the function of mesenchymal stromal cells (MSC) in patients with MDS, AML with myelodysplasia-related changes (MRC), a well-recognized clinical subtype of secondary AML, andde novoAML. We observed a significant inhibitory effect of MDS-MSC on T lymphocyte proliferation and no significant differences in any of the cytokines tested. AML-MSC inhibited T-cell proliferation only at a very low MSC/T cell ratio. When compared to the control, AML-MRCderived MSC presented a significant increase inIL6expression, whereasde novoAML MSC presented a significant increase in the expression levels ofVEGFA, CXCL12, RPGE2, IDO, IL1β, IL6andIL32, followed by a decrease inIL10expression. Furthermore, data indicate that IL-32 regulates stromal cell proliferation, has a chemotactic potential and participates in stromal cell crosstalk with leukemia cells, which could result in chemoresistance. Our results suggest that the differences between AML-MRC andde novoAML also extend into the leukemic stem cell niche and that IL-32 can participate in the regulation of the bone marrow cytokine milieu.

1 May 2013 in Leukemia Research
Verified
Journal Article
Closed access
MLMatheus Rodrigues Lopes
Matheus Rodrigues Lopes
FTFabiola Traina
Fabiola Traina
PCPaula de Melo Campos
Paula de Melo Campos
JPJoão Kleber Novais Pereira
João Kleber Novais Pereira
JMJoão Agostinho Machado-Neto
João Agostinho Machado-Neto
PFPatricia Favaro
Patricia Favaro

1 January 2022 in Jornal Vascular Brasileiro
Verified
Journal Article
Open access
LLLorrany Junia Lopes de Lima
Lorrany Junia Lopes de Lima
MLMatheus Rodrigues Lopes
Matheus Rodrigues Lopes
CFCarlos Alberto de Lima Botelho Filho
Carlos Alberto de Lima Botelho Filho
RCRoberta Stofeles Cecon
Roberta Stofeles Cecon
Resumo Contexto O pé diabético é uma complicação do diabetes melito (DM), sendo a maior causa de amputação dos membros inferiores. Objetivos Avaliar a prática de medidas de autocuidado com os pés, segundo sexo e escolaridade, em pacientes portadores de DM na região nordeste no estado da Bahia. Métodos Estudo quantitativo, observacional, analítico, transversal, realizado com 88 pacientes portadores de DM, em consulta de rotina, de fevereiro a março de 2020. A coleta de dados foi executada através da aplicação de questionários socioeconômico e do autocuidado com os pés (conhecimento sobre pé diabético, hábitos de cuidado/inspeção dos pés e procura pela Unidade de Saúde na presença de alterações com a saúde dos pés). Resultados Do total, 58% dos indivíduos desconhecia o termo “pé diabético”, porém possuíam cuidados mínimos adequados com os pés, como inspecioná-los (60,2%), hidratá-los (65,9%), não andar descalço (81,8%) e cortar as unhas (92%), apesar de 90,9% não utilizar sapatos considerados adequados. Houve relação entre menor nível de escolaridade e pior desempenho nas questões referentes a andar descalço, hidratar os pés, cortar as unhas, usar calçados adequados e identificar micoses (p < 0,05), porém não houve associação da realização das medidas de autocuidado e sexo. Conclusão Os portadores de DM entrevistados não realizaram todas as medidas de autocuidado com os pés e desconheciam o termo “pé diabético”. Houve associação entre menor escolaridade e menor capacidade de realização dessas medidas, o que sugere que o letramento em saúde seria importante para melhoria desse autocuidado, contribuindo para diminuição de complicações e amputações dos pés.

1 July 2017 in Stem Cell Research
Verified
Journal Article
Open access
BPBruna Palodetto
Bruna Palodetto
ADAdriana da Silva Santos Duarte
Adriana da Silva Santos Duarte
MLMatheus Rodrigues Lopes
Matheus Rodrigues Lopes
FCFlavia Adolfo Corrocher
Flavia Adolfo Corrocher
FRFernanda Marconi Roversi
Fernanda Marconi Roversi
SSSARA Teresinha OLALLA SAAD
SARA Teresinha OLALLA SAAD
Cross-talk between hematopoietic stem cells (HSCs) and bone marrow stromal cells (BMSCs) is essential for HSCs regulation and leukemogenesis. Studying bone marrow of myelodysplasia patients, a pre-leukemic condition, we found mRNA overexpression of vascular endothelial growth factor A (VEGFA) in CD34+ HSCs and semaphorin 3A (SEMA3A) in BMSCs. To better understand the role of VEGFA and SEMA3A in leukemogenesis, we recruited 30 myelodysplastic syndrome (MDS) patients, 29 acute myeloid leukemia (6 secondary to MDS) patients and 12 controls. We found higher VEGFA expression in de novo AML patients (without prior MDS) group (p=0.0073) and higher SEMA3A expression in all BMSCs patient's samples compared to control group. We then overexpressed VEGFA in an acute myelogenous leukemia cell line, KG1 cells, and in normal CD34+ cells. This overexpression increased KG1 (p=0.045) and CD34+ cell (p=0.042) viability and KG1 (p=0.042) and CD34+ cell (p=0.047) proliferation. Moreover, KG1 and CD34+ cells overexpressing VEGFA also had increased proliferation when co-cultured with human marrow stromal HS5 cells (p=0.045 and p=0.02, respectively). However, co-culture of these transformed cells with HS5 cells overexpressing SEMA3A reduced KG1 (p=0.004) and CD34+ (p=0.009) proliferation. Co-culture of KG1 transformed cells with HS27 cells overexpressing SEMA3A reduced KG1 proliferation as well (p=0.01). To investigate whether the dominant SEMA3A effect over VEGFA could be due to competition for neuropilin1 receptor (NRP1), we performed immunoprecipitation with anti-NRP1 antibody of cell extracts of co-cultured KG1 and HS5 cells, induced or not by VEGFA and SEMA3A recombinant proteins. Results showed a preferential association of NRP1 with SEMA3A, suggesting that SEMA3A can partially reverse the effects caused by the VEGFA preventing its binding with the NRP1 receptor. Since both hematopoietic cells, leukemic and normal, showed similar behavior, we suppose that the attempt to reversion of VEGF effects by SEMA3A is a homeostatic phenomenon in the hematopoietic niche. Finally, we conclude that VEGFA overexpression confers AML cell advantages and SEMA3A may partially reverse this effect; thus, SEMA3A protein combined with VEGFA inhibitors could be beneficial for AML treatment.

1 February 2021 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
EMErika Andressa Simões de Melo
Erika Andressa Simões de Melo
LFLaryssa Elza de Santana Ferreira
Laryssa Elza de Santana Ferreira
RCRodolfo José Ferreira Cavalcanti
Rodolfo José Ferreira Cavalcanti
CFCarlos Alberto de Lima Botelho Filho
Carlos Alberto de Lima Botelho Filho
MLMatheus Rodrigues Lopes
Matheus Rodrigues Lopes
RBRomero Henrique de Almeida Barbosa
Romero Henrique de Almeida Barbosa
The aim of this study was to highlight the differences between the cardiometabolic effects and the cardiovascular risk of physical inactivity and sedentary behavior. A narrative bibliographic review was conducted. In the research, national and international articles were selected from the PubMed, SciELO, and LILACS databases using the descriptors "sedentary lifestyle, cardiovascular risk, physical inactivity, sedentary behavior, and cardiovascular risks." Both physical inactivity and sedentary behavior are related to metabolic and organic changes, promoting a chronic proinflammatory state, cardiac remodeling, increased body adiposity, and skeletal muscle dysfunction. It is possibly stated that both of them result in a higher risk of developing chronic diseases, resulting in higher global and cardiovascular morbidity and mortality, with nuances in their intrinsic effects. It is inferred that both physical inactivity and sedentary behavior are cardiovascular risk factors that can be modified with the correct clinical approach. It is necessary to differentiate physically inactive individuals from those with a high number of sedentary behaviors. These concepts need better clinical applicability to improve the prevention of primary and secondary cardiovascular risks.